Aarti Drugs Ltd

Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Drugs Ltd has seen its investment rating downgraded from Hold to Sell as of 21 May 2026, reflecting a nuanced reassessment across quality, valuation, financial trend, and technical parameters. Despite recent positive quarterly financial results, concerns over long-term growth and relative underperformance against benchmarks have weighed heavily on the outlook for this small-cap pharmaceutical player.

Aarti Drugs Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, reflecting a more compelling price proposition for investors within the Pharmaceuticals & Biotechnology sector. Despite recent market headwinds and a modest decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more favourable entry point relative to historical averages and peer benchmarks.

Aarti Drugs Ltd., a prominent manufacturer of active pharmaceutical ingredients (APIs), pharma intermediates, and speciality chemicals, reported a mixed performance for Q4 FY26 (January-March 2026), with net profit declining 12.20% year-on-year to ₹55.19 crores despite a strong sequential recovery. The ₹3,319 crore market cap company witnessed its stock trading at ₹367.85 on May 15, 2026, down 20.07% over the past year, significantly underperforming both the benchmark indices and its sector peers.

Aarti Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 May 2026. While the rating was revised on this date, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with the most recent insights into the company’s performance and outlook.

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aarti Drugs Ltd has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting nuanced changes in key indicators such as MACD, RSI, and moving averages. Despite a modest day gain of 1.12%, the pharmaceutical company’s technical landscape remains complex, with mixed signals across weekly and monthly charts suggesting cautious investor sentiment amid broader market challenges.

Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026, reflecting a nuanced reassessment of its financial performance, valuation metrics, management efficiency, and technical indicators. Despite ongoing challenges in profitability and operating trends, certain valuation and efficiency parameters have improved, prompting a more balanced outlook for this small-cap pharmaceutical player.

The Sensex declined by 2.15% on 1 Apr 2026, yet Aarti Drugs Ltd surged 7.65%, marking a 6.28 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, raising the question of whether this is a genuine recovery or a technical bounce within a broader downtrend.

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.